What is HC Wainwright’s Estimate for NMRA FY2024 Earnings?

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Neumora Therapeutics in a report released on Wednesday, November 13th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($1.63) per share for the year, down from their previous forecast of ($1.37). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q4 2024 earnings at ($0.46) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.37) EPS and FY2028 earnings at $0.03 EPS.

Several other research analysts have also recently commented on the company. Needham & Company LLC reissued a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Wednesday. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.67.

Neumora Therapeutics Trading Down 7.3 %

Neumora Therapeutics stock opened at $10.84 on Friday. The company has a fifty day simple moving average of $13.10 and a 200 day simple moving average of $11.44. Neumora Therapeutics has a 1-year low of $8.33 and a 1-year high of $21.00. The company has a market cap of $1.75 billion, a P/E ratio of -5.80 and a beta of 3.92.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the prior year, the company earned ($1.14) EPS.

Insider Transactions at Neumora Therapeutics

In related news, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares in the company, valued at approximately $342,303. The trade was a 41.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now directly owns 322,966 shares in the company, valued at approximately $4,847,719.66. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,538 shares of company stock worth $1,390,513 over the last quarter. Company insiders own 26.40% of the company’s stock.

Institutional Trading of Neumora Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Amalgamated Bank raised its position in Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after purchasing an additional 2,402 shares in the last quarter. Handelsbanken Fonder AB increased its stake in shares of Neumora Therapeutics by 35.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock valued at $351,000 after purchasing an additional 6,900 shares during the last quarter. Quarry LP acquired a new position in shares of Neumora Therapeutics during the 2nd quarter worth $98,000. Intech Investment Management LLC bought a new stake in shares of Neumora Therapeutics during the 3rd quarter worth $175,000. Finally, Ballentine Partners LLC acquired a new stake in Neumora Therapeutics in the third quarter valued at about $178,000. Institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.